El, Kimberley http://orcid.org/0000-0002-5550-1684
Douros, Jonathan D.
Willard, Francis S. http://orcid.org/0000-0002-4260-2451
Novikoff, Aaron http://orcid.org/0000-0002-4838-001X
Sargsyan, Ashot http://orcid.org/0000-0003-1662-7548
Perez-Tilve, Diego http://orcid.org/0000-0002-0351-4133
Wainscott, David B.
Yang, Bin http://orcid.org/0000-0003-1180-6184
Chen, Alex http://orcid.org/0000-0001-5666-391X
Wothe, Donald
Coupland, Callum http://orcid.org/0000-0001-8921-3616
Tschöp, Mattias H. http://orcid.org/0000-0002-4744-371X
Finan, Brian http://orcid.org/0000-0002-6467-0447
D’Alessio, David A. http://orcid.org/0000-0003-4155-4870
Sloop, Kyle W. http://orcid.org/0000-0001-6748-9929
Müller, Timo D. http://orcid.org/0000-0002-0624-9339
Campbell, Jonathan E. http://orcid.org/0000-0003-4358-6331
Article History
Received: 21 November 2022
Accepted: 21 April 2023
First Online: 5 June 2023
Competing interests
: The Campbell group receives funding for basic science from Novo Nordisk and Eli Lilly. The Müller group receives funding for basic science from Novo Nordisk. F.S.W., D.B.W. and K.W.S. are employees of Eli Lilly. J.D.D., B.Y. and B.F. are employees of Novo Nordisk. D.A.D. has served as a consultant or speaker within the past 12 months for Eli Lilly and Structure Therapeutics. J.E.C. has served as a consultant or speaker within the past 12 months for Structure Therapeutics. The remaining authors declare no competing interests or conflict of interest.